S. 3560 · 112th Congress
Recalcitrant Cancer Research Act of 2012
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 112th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
WhitehouseSponsor23 cosponsors · 14 D, 8 R, 1 I
D
Akaka
RB
R
Blunt
SB
D
Brown
SB
R
Brown
RB
D
Blumenthal
SC
R
Collins
CG
R
Grassley
FL
D
Lautenberg
RL
R
Lugar
BM
D
Mikulski
MP
D
Pryor
JR
D
Reed
MR
R
Rubio
DS
D
Stabenow
JT
D
Tester
RW
R
Wicker
MW
D
Warner
DF
D
Feinstein
MK
R
Kirk
JL
I
Lieberman
BN
D
Nelson
JS
D
Shaheen
PL
D
Leahy17 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes: (1) a review of the status of research, such as a summary of findings,…
What it does: CRS summary · Introduced in Senate · Sep 19, 2012
Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes: (1) a review of the status of research, such as a summary of findings, identification of promising scientific advances, a description of the availability of qualified scientific researchers, and the identification of resources available to facilitate research; (2) identification of research questions that have not been adequately addressed; and (3) recommendations for actions to advance research and for appropriate benchmarks to measure progress on achieving such actions. Requires the Director to develop the framework within 18 months and review and update it every 5 years.
Requires the Director to identify within 6 months 2 or more recalcitrant cancers that have a 5-year relative survival rate of less than 20%, and are estimated to cause the death of at least 30,000 individuals in the United States per year. Authorizes the Director to identify additional such cancers and to consider additional metrics of progress (such as incidence and mortality rates) against such cancer.
Requires the Director to convene a working group for each identified cancer to provide expertise on, and assist in developing, a scientific framework under this Act.
Requires the Director to consider each relevant scientific framework developed under this Act when making recommendations for exception funding for grant applications.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Recalcitrant Cancer Research Act of 2012
Latest action (Sep 19, 2012): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Sep 19, 2012
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.